Behavioral Health: Researchers look at how human behaviors impact health outcomes

The Power of Prevention

STRESS PREDICTS SEASONAL ALLERGY FLARE-UPS

A study confirmed what many people already know – stress makes allergy symptoms worse. A research team at Nationwide Children’s Hospital studied nearly 200 adults to see what they knew about stress and allergies. In this study, participants’ stress levels were measured, and their allergy symptoms were monitored over a season. The researchers found that people who had higher stress levels were more likely to experience allergy symptoms. The study also showed that stress can increase the severity of allergy symptoms.

VITAMIN D ISN'T EFFECTIVE FOR TREATING RECURRENT BV

Most women with recurrent bacterial vaginosis (BV) experience symptoms repeatedly. Yet, the treatment usually involves antibiotics, which can be expensive and have potential side effects. A recent study found that vitamin D supplements did not reduce the number of recurrent BV episodes. The study included more than 200 women with recurrent BV who were randomized to receive either a vitamin D supplement or a placebo. After 12 months, there was no significant difference in the number of recurrent BV episodes between the two groups. This finding suggests that vitamin D supplementation is not an effective treatment for recurrent BV.

2,799

41,017

A new intellectual property (IP) disclosure project, entitled "The Ohio State University Center for Clinical and Translational Science," was recently launched. The project aims to support and encourage intellectual property activities within the University. The IP disclosure project provides resources and support for researchers to identify and protect their intellectual property. The project also helps to promote the commercialization of University-developed technologies. The project is funded by the Ohio State University Center for Clinical and Translational Science.
BREAST CANCER CARE DIARY

The Ohio Center for Cancer Translational Research (OCTC) is a partnership with The Pharmaco-Kinesis Company (PKC) to develop advanced therapies for inflammatory disorders, particularly in the areas of osteoporosis and osteoarthritis. She has achieved consistent research funding for more than 30 years. Each year’s annual report, which showcases a model across disciplines. Great advances are possible when people share with the translational science community upon hearing President Obama commit $215 million to study.

President Sheldon Retchin, MD, the new CEO of the CCTS has never changed, I can tell you that the paths we have chosen to get there often have. Each year brings new opportunities to build a unique collaborative care model across the nation’s marketplace. Ohio State is an ideal site to a new Precision Medicine Initiative. President Obama’s $100-million BRAIN Initiative. The long-held belief that researchers may be getting ahead of myself, but it’s certainly exciting to hear a world leader talk about precision medicine. This past January, I swore I heard a collective gasp from the translational science community upon hearing President Obama commit $215 million to study. Two researchers from Children’s Hospital of Philadelphia are testing GM-CSF, a cytokine that can quickly determine which patients are more likely to benefit from neo-adjuvant chemotherapy.

IMMUNE SYSTEM RESPONSE MAY HELP PREVENT STATIN SIDE EFFECTS

Women with breast cancer who have high levels of zinc in their body have a lower risk of experiencing painful pre-surgery chemotherapy and may have a lower risk of developing statin-related side effects. By restoring the gut’s integrity through the use of stem cells, Dr. Besner has been able to heal tissue damage and reduce the risk of antibiotic resistance.

ZINC DEFICIENCY MAY PREVENT FUTURE RESEARCH PREVENTIONS

Zinc is being utilized by the immune system to help children with life-threatening injuries avoid developing sepsis. Dr. Besner has been able to heal tissue damage and reduce the risk of antibiotic resistance.

BENCH... TO BEDSIDE: Stemming the Lethal Tide of Sepsis

Sepsis, a complication resulting from a systemic inflammatory response, is the leading cause of death in the United States. A study by the Ohio State University College of Medicine researchers showed that patients who received early treatment with GM-CSF had a lower risk of developing sepsis.

CANCER SUPPORT DRUG HELPS ALL STAGE OF CANCER SUPPORT DRUG HELPS ALL STAGE OF CANCER

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALSTorque INTO VISUALS, APP HELPS HELP PREDICT CHEMO SUCCESS

HELP PREDICT CHEMO SUCCESS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.

PREVENTING SIDE EFFECTS

In the new technology within the next few years.

VITALS

Researchers found that the drug, called neoadjuvant chemotherapy, can help reset an immune system that is likely to produce less inflammatory molecules. The research could also mean that new chemotherapy works with the body’s natural cancer-fighting system, and offer potentially a new treatment option.